The University of North Carolina at Chapel Hill's technology is based on set of patient-cell derived gene signatures for classifying four pancreatic subtypes.
Fleury will integrate IDbyDNA's Explify platform into its own laboratory workflow and develop a full suite of Explify-based clinical testing.
Under the terms of the agreements, Thermo Fisher obtains global non-exclusive rights to products, tools, and research services involving the technologies.
Expedeon's colloidal gold is an aqueous suspension of uniform, spherical metallic nanoparticles that can conjugate to antibodies and antigens.
The agreement will enable Biocartis to commercialize the EGFR S492R resistance mutation as part of its liquid and solid biopsy RUO assays.
The company recently licensed the university's system, which codes pathology reports in SNOMED and generates HL7 messages.
LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
The company said it plans to use the technology to derive clinical insights from the large-scale proteomic datasets generated by its SomaScan platform.
The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.
The NMI Natural and Medical Sciences Institute at the university and its affiliate will use the patents to expand their cell-based research service offerings.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.